news > tag > lu-177

isoSolutions Offers GMP Grade Non-carrier Added Lutetium-177

David T. Drummond ⎜Nov 19, 2018 ⎜ Industry

An agreement signed with SpectronRx, an Indiana, USA radiopharmaceutical manufacturer, designates isoSolutions as the exclusive distributor in Latin America and Canada of Spectron’s GMP grade non-carrier added (nca) Lutetium-177 radiochemical.

Non-carrier added (nca) Lutetium-177 (Lu-177) is a radioisotope used for therapeutic purposes. (more…)

Tags:

Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors

Kevin Yang ⎜Nov 5, 2018 ⎜ Industry

Radiolabeled somatostatin analog therapy has become an established treatment method for patients with well to moderately differentiated unresectable or metastatic neuroendocrine tumors (NETs). The most frequently used somatostatin analogs in clinical practice are octreotide and octreotate. (more…)

Tags:

First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Kevin Yang ⎜Sep 12, 2018 ⎜ Industry

This first-in-human study demonstrated that 177Lu-EB-PSMA-617 had higher accumulation in mCRPC and that low imaging dose appears to be effective in treating tumors with high 68Ga-PSMA-617 uptakes. Elevated uptakes of 177Lu-EBPSMA-617 in kidneys and red bone marrow were well tolerated at the administered low dose. Further investigations with increased dose and frequency of administration are warranted. (more…)

Tags:

Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors

Kevin Yang ⎜Sep 6, 2018 ⎜ Industry

Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide. Prostate-specific membrane antigen (PSMA) is a surface molecule specifically expressed by prostate tumors and has been shown to be a valid target for internal radionuclide therapy in both preclinical and clinical settings. The most common radiotherapeutic agent is the small molecule 177Lu-PSMA-617, (more…)

Tags:

United Pharmacy Partners (UPPI, LLC) 2018 Annual Meeting

Patricia Acton ⎜Sep 5, 2018 ⎜ Calendar

isoSolutions will be attending the United Pharmacy Partners (UPPI, LLC) 2018 Annual Meeting to be held in San Antonio, TX September 12 to 15, 2018. (more…)

Tags:

2018 Chinese Society of Nuclear Medicine Annual Meeting

Hans Peng ⎜Aug 2, 2018 ⎜ Industry

Since China was the highlighted country of 2018 SNMMI in Philadelphia, several CSNM board members presented a brief report of 2018 SNMMI to the audience. One interesting fact needs attention is that Lu-177 is the most discussed topic this year not only because Lu-177 is highly in demand during SNMMI, but also more and more professors and doctors in China have realized how important and effective Lu-177 is when it is used to diagnose and treat prostate cancer. (more…)

Tags:

SNMMI Image of the Year: PSMA PET Imaging of Theranostic for Advanced Prostate Cancer

David T. Drummond ⎜Jun 29, 2018 ⎜ Industry

PHILADELPHIA (Embargoed until 6:30 p.m. EDT, Tuesday, June 26, 2018) – In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to radionuclide therapy targeting prostate specific membrane antigen (PSMA) with the radionuclide lutetium-177 (177Lu). (more…)

Tags: